RecruitingNCT06354465

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews


Sponsor

Lifespan

Enrollment

25 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • English speaking
  • Over the age of 18
  • Diagnosed with opioid use disorder
  • \- Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program

Exclusion Criteria1

  • \- If not permitted by their organizational union to participate

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Rhode Island Department of Corrections

Cranston, Rhode Island, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06354465